Targeted Oncology - Immunotherapy, Biomarkers, and …
WEBIn an interview, Jaime Merchan, MD, explained the background and data from a biomarker analysis of the CLEAR trial in advanced renal cell carcinoma. Targeted Oncology provides news, videos, and reviews on …
FDA Approves Isatuximab Plus VRd in Transplant-Ineligible …
WEB4 hours ago · The FDA has approved isatuximab (Sarclisa) plus bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (VRd) for the treatment of patients with …
FDA Clears Amivantamab/Chemotherapy Combo in EGFR-Mutant …
WEB11 hours ago · The FDA approved amivantamab-vmjw (Rybrevant) plus carboplatin and pemetrexed for the treatment of locally advanced or metastatic non–small cell lung …
BAY 2927088 Shows Promise in HER2-Mutant NSCLC
WEB5 hours ago · BAY 2927088, an oral, reversible tyrosine kinase inhibitor (TKI) that potently inhibits mutant HER2, led to promising response rates when used for the treatment of …
Targeting AML: The Latest Advances
WEB10 hours ago · Patients with acute myeloid leukemia (AML) have benefited from recent advancements in treatment. The advent of drugs targeting specific genetic mutations, …
FDA Clears Investigational New Drug Application for CD-001 in …
WEB9 hours ago · The IND application of CD-001 has been cleared by the FDA. 1. CD-001 is a therapy that is designed to target PD-1–positive, CD8-positive T cells using an anti …
Epigenomic Liquid Biopsy for Detecting Tumor PSMA in Prostate …
WEB7 hours ago · 0:09 | The objective of our study at ESMO was to evaluate whether a new epigenomic liquid biopsy tool could non invasively detect tumor PSMA expression in …
FDA Approves New Dosage of Trastuzumab Biosimilar for HER2 ...
WEB1 day ago · The agent is approved to treat HER2-overexpressing cancers. In April 2024, the FDA approved the 150-mg dose of trastuzumab-strf. Trastuzumab-strf, a trastuzumab …
News - Targeted Oncology
WEBMorgan Bayer. September 15th 2024. The FDA granted IBI363 fast track status for melanoma and approved a ready-to-use subcutaneous bortezomib for MM and MCL. …
Continuing Osimertinib Treatment After Progression Prolongs …
WEBJan 25, 2019 · The investigators said that continuing osimertinib after progression, alone or in conjunction with radiotherapy, may provide prolonged clinical benefit in selected …